AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

Given that the Australian government heavily subsidizes pharmaceuticals— spending more than $AU16.7 billion annually through the Pharmaceutical Benefits Scheme (PBS)—there is both a strong moral and ...